Table 4 Comparison of antibiotics and related treatments in elderly bedridden patients with hip fracture and lower respiratory tract infection

 Second-generation cephalosporins

10 (9.9%)

3 (6.5%)

4 (17.4%)

3 (9.4%)

0.353

 Third-generation cephalosporins (without enzyme inhibitors)

31 (30.7%)

18 (39.1%)

5 (21.7%)

8 (25.1%)

0.235

  Third-generation cephalosporins (with enzyme inhibitors)

22 (21.8%)

5 (10.9%)

11 (47.8%)

6 (18.8%)

0.002

  4th-generation cephalosporin

1 (1%)

0 (0)

0 (0)

1 (3.1%)

0.545

  Carbapenems

31 (30.7%)

17 (37%)

1 (4.3%)

13 (40.6%)

0.007

  Quinolones

7 (7%)

2 (4.3%)

3 (13%)

2 (6.3%)

0.469

  Glycopeptides

4 (4%)

2 (4.3%)

0 (0)

2 (6.3%)

0.685

  Clindamycin

1 (1%)

1 (2.2%)

0 (0)

0 (0)

1.000

 Antibiotics need to be upgraded

32 (31.7%)

7 (15.2%)

8 (34.8%)

17 (53.1%)

0.002

 Upgrade M (IQR) on the X-day of admission

6 (3.5–7)

5 (3–7)

6 (4–10)

6.5 (3.0–7.5)

0.259

  Number of antibiotic upgrades M (IQR)

0 (0–1)

0 (0–0)

0 (0–1)

1 (0–2)

0.001

Antifungal therapy

32 (31.7%)

6 (13.0%)

6 (26.1%)

20 (62.5%)

< 0.001

 Fluconazole is preferred

17 (16.8%)

3 (6.5%)

5 (21.7%)

9 (28.1%)

0.032

 Upgrading ratio of antifungal drugs

3 (9.38%)

0 (0)

1 (16.7%)

2 (10%)

1.000

Upgrade M (IQR) on the X-day of admission

8.5 (5–15.5)

5.5 (4–13)

7 (7–10)

11.5 (5.5–20)

0.407

 Upgrading times of antifungal agents M (IQR)

1 (1–1)

-

1

1

-

Need parenteral nutrition support

26 (25.7%)

6 (13%)

6 (26.1%)

14 (43.8%)

0.010

Use of glucocorticoids

12 (11.9%)

5 (10.9%)

1 (4.3%)

6 (18.8%)

0.255

 Intravenous glucocorticoid

9 (8.91%)

2 (4.3%)

1 (4.3%)

6 (18.8%)

 Oral glucocorticoid

3 (2.97%)

3 (6.5%)

0

0

0.086

 Not used

89 (88.12%)

41 (89.1%)

22 (95.7%)

26 (81.3%)

Tracheal intubation/incision

9 (8.9%)

2 (4.3%)

1 (4.3%)

6 (18.8%)

0.061